Efficacy News and Research

RSS
Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting

First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury

XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

Genta reports combined data from Genasense Phase 3 trials for advanced melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.